HUTCHMED (China) Ltd
00013
Company Profile
Business description
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Contact
2 Queen's Road Central
48th Floor, Cheung Kong Center
Hong Kong
HKGT: +852 2121 8200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,796
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
Consumer caution dents growth, shares look cheap.
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Income opportunities remain beneath the surface.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,144.70 | 60.50 | -0.66% |
| CAC 40 | 8,139.00 | 66.37 | -0.81% |
| DAX 40 | 25,794.12 | 530.89 | -2.02% |
| Dow JONES (US) | 51,550.55 | 27.49 | 0.05% |
| FTSE 100 | 10,673.94 | 108.72 | -1.01% |
| HKSE | 24,481.86 | 315.12 | -1.27% |
| NASDAQ | 24,712.59 | 397.60 | 1.64% |
| Nikkei 225 | 57,434.77 | 3,643.13 | -5.96% |
| NZX 50 Index | 13,998.50 | 92.47 | -0.66% |
| S&P 500 | 7,421.96 | 68.23 | 0.93% |
| S&P/ASX 200 | 9,020.80 | 44.30 | -0.49% |
| SSE Composite Index | 3,649.18 | 40.73 | -1.10% |